The use of Olaparib in special populations needs to be adjusted according to pregnancy, lactation, liver and kidney function, and other conditions. The following classification explains medication precautions and contraindications to ensure treatment safety and effectiveness.

1. Pregnant women

(1) Based on animal research, olaparib may cause fetal malformations or miscarriage, and is contraindicated for pregnant women.

(2) Women of childbearing age should confirm their pregnancy status before taking medication, and take effective contraceptive measures during treatment and at least one month after discontinuing medication.

2. Lactating women

(1) It is not clear whether olaparib is secreted into human milk, but animal data shows that the drug can enter breast milk.

(2) It is recommended to suspend breastfeeding during the treatment period and within one month after the last dose to avoid potential risks to the infant.

3. Pediatric patients

(1) The safety and efficacy of patients under 18 years old have not been established, and there is currently no recommended dosage.

(2) It should be used after careful evaluation by a doctor to weigh the pros and cons.

4. Elderly patients

(1) There is no significant difference in pharmacodynamics between patients over 65 years old and young people, but individual sensitivity should be noted.

(2) Elderly patients are more prone to adverse reactions such as bone marrow suppression, and monitoring needs to be strengthened.

5. Patients with liver dysfunction

(1) Mild or moderate liver dysfunction (Child Pugh A/B grade) does not require dose adjustment.

(2) Patients with severe liver function impairment (Child Pugh C grade) should avoid use as it may increase drug exposure.

6. Patients with renal insufficiency

(1) Mild to moderate renal insufficiency (creatinine clearance rate ≥ 31mL/min) does not require dose adjustment.

(2) Patients with severe renal insufficiency (creatinine clearance rate ≤ 30mL/min) or end-stage renal disease should reduce their dosage and closely monitor for adverse reactions.

7. Reproductive potential population

(1) Male patients should avoid sperm donation during treatment and for 3 months after discontinuing medication, as medication may affect sperm quality.

(2) Both men and women with fertility plans need to consult a doctor and assess potential risks before taking medication.